The findings based on validated patient reported outcomes (PRO) questionnaires completed by participants in the DUAL™ V trial were announced today at the 51st European Association for the Study of Diabetes (EASD) in Stockholm, Sweden (Novo Nordisk)
Diabetes News
Tag: Xultophy
Xultophy
New Xultophy® (IDegLira) phase 3b study showed statistically significant HbA1c reduction, body weight change and lower rate of hypoglycaemia versus insulin glargine (Novo Nordisk)
Glycosmedia is also available as an App: